Relmada Therapeutics Inc (RLMD)

12:14 PM

Relmada Therapeutics Moves: Max Kates Joins Advisory Board - StocksToTrade

12:14 PM

08:55 AM

Relmada Therapeutics (RLMD) Advances Phase 3 Plans for Bladder C - GuruFocus

08:55 AM

08:51 AM

Relmada Therapeutics prices $100M securities offering - MSN

08:51 AM

08:47 AM

Relmada Therapeutics (RLMD) Launches $100 Million Stock and Warr - GuruFocus

08:47 AM

08:37 AM

Relmada Therapeutics stock falls after $100 million share offering By Investing.com - Investing.com UK

08:37 AM

08:34 AM

Relmada Therapeutics stock falls after $100 million share offering - Investing.com

08:34 AM

08:07 AM

Relmada Therapeutics prices $100 million stock offering at $2.20 per share - Investing.com

08:07 AM

07:40 AM

Relmada Therapeutics Receives FDA Feedback on NDV-01 Trials - TipRanks

07:40 AM

07:35 AM

Relmada’s NDV-01 shows 92% response rate in bladder cancer - Investing.com

07:35 AM

07:27 AM

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - The Manila Times

07:27 AM

07:15 AM

Relmada Therapeutics Announces 9-Month Follow-Up Safety and Efficacy Data for NDV-01 in Non-Muscle Invasive Bladder Cancer, with FDA Support for Future Registrational Trials - Quiver Quantitative

07:15 AM

07:09 AM

Relmada Therapeutics (NASDAQ: RLMD) prices 40,142,000-share offering for $100M - Stock Titan

07:09 AM

07:01 AM

Relmada (NASDAQ: RLMD) posts 92% ORR in NMIBC as FDA supports two Phase 3 paths - Stock Titan

07:01 AM

04:18 AM

Why Relmada Therapeutics Inc. stock remains a top recommendationJuly 2025 Chart Watch & Precise Entry and Exit Recommendations - newser.com

04:18 AM

04:14 AM

What institutional flow reveals about Relmada Therapeutics Inc.Long Setup & Weekly Watchlist of Top Performers - newser.com

04:14 AM

01:09 AM

Will Relmada Therapeutics Inc. stock recover faster than marketMarket Volume Summary & Low Risk Entry Point Guides - newser.com

01:09 AM

Nov 03, 2025

Smart tools for monitoring Relmada Therapeutics Inc.’s price actionJuly 2025 Weekly Recap & Fast Exit and Entry Strategy Plans - newser.com

Nov 03, 2025

Nov 03, 2025

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Short Interest Update - MarketBeat

Nov 03, 2025

Nov 03, 2025

What to expect from Relmada Therapeutics Inc. in the next 30 days - newser.com

Nov 03, 2025

Nov 03, 2025

Is Relmada Therapeutics Inc. building a consolidation baseJuly 2025 Trends & Low Risk Profit Maximizing Plans - newser.com

Nov 03, 2025

Nov 03, 2025

Is Relmada Therapeutics Inc. stock ready for a breakoutEarnings Growth Summary & Fast Gain Stock Trading Tips - newser.com

Nov 03, 2025

Nov 03, 2025

Why Relmada Therapeutics Inc. stock is a value investor pickJuly 2025 EndofMonth & Fast Momentum Entry Tips - newser.com

Nov 03, 2025

Nov 03, 2025

Will breakout in Relmada Therapeutics Inc. lead to full recoveryNew Guidance & Community Trade Idea Sharing - newser.com

Nov 03, 2025

Nov 03, 2025

Is Relmada Therapeutics Inc. showing signs of accumulation2025 Technical Patterns & Fast Entry High Yield Tips - newser.com

Nov 03, 2025

Nov 02, 2025

Will Relmada Therapeutics Inc. (4E2) stock beat revenue estimatesWall Street Watch & Stock Portfolio Risk Control - newser.com

Nov 02, 2025

Nov 02, 2025

Why Relmada Therapeutics Inc. stock attracts global investors2025 Growth vs Value & Daily Momentum Trading Reports - newser.com

Nov 02, 2025

Nov 02, 2025

Will Relmada Therapeutics Inc. stock gain from lower inflationIndex Update & Low Risk High Reward Ideas - newser.com

Nov 02, 2025

Nov 01, 2025

Relmada Therapeutics (NASDAQ:RLMD) Given Sell (E+) Rating at Weiss Ratings - MarketBeat

Nov 01, 2025

Nov 01, 2025

AdvisorShares Investments LLC Raises Stock Holdings in Relmada Therapeutics, Inc. $RLMD - MarketBeat

Nov 01, 2025

Oct 31, 2025

Relmada Therapeutics (RLMD) to Release Earnings on Thursday - MarketBeat

Oct 31, 2025